NASDAQ : ACTU
Actuate Therapeutics, Inc. — Financial statements
Healthcare · Biotechnology · United States
Last price 0.3351 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 18.43M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Financial statements
Income statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Selling, General & Admin | 11.83M | 12.20M | 6.48M | 3.27M | 3.82M |
| Research & Development | 8.94M | 10.29M | 18.68M | 21.71M | 16.39M |
| Operating Expenses | 20.77M | 22.50M | 25.16M | 24.97M | 20.21M |
| Operating Income | -20.77M | -22.50M | -25.16M | -24.97M | -20.21M |
| Interest Expense | -20.25K | -20.25K | -18.72K | -43.64K | -16.20K |
| Interest & Investment Income | 339.84K | 287.71K | 222.29K | 352.67K | 27.03K |
| Other Non Operating Income (Expenses) | 264.34K | -79.82K | 36.58K | ||
| EBT Excluding Unusual Items | -20.45M | -22.23M | -24.69M | -24.74M | -20.16M |
| Other Unusual Items | -2.59M | ||||
| Pretax Income | -20.45M | -22.23M | -27.29M | -24.74M | -20.16M |
| Net Income | -20.45M | -22.23M | -27.29M | -24.74M | -20.16M |
| Net Income to Common | -20.45M | -22.23M | -27.29M | -24.74M | -20.16M |
| Shares Outstanding (Basic) | 23.09M | 21.02M | 8.37M | 1.43M | 1.21M |
| Shares Outstanding (Diluted) | 23.09M | 21.02M | 8.37M | 1.43M | 1.21M |
| EPS (Basic) | -0.89 | -1.06 | -3.26 | -17.24 | -16.65 |
| EPS (Diluted) | -0.89 | -1.06 | -3.26 | -17.24 | -16.65 |
| EBIT | -20.77M | -22.50M | -25.16M | -24.97M | -20.21M |
Balance sheet
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Cash & Equivalents | 4.43M | 13.16M | 8.64M | 2.96M | 20.45M |
| Cash & Short-Term Investments | 4.43M | 13.16M | 8.64M | 2.96M | 20.45M |
| Prepaid Expenses | 322.10K | 484.00K | 566.28K | 36.91K | 33.75K |
| Total Current Assets | 4.75M | 13.64M | 9.21M | 3.00M | 20.48M |
| Long-Term Deferred Charges | 451.40K | 392.49K | 110.55K | ||
| Total Assets | 5.20M | 14.04M | 9.32M | 3.00M | 20.48M |
| Accounts Payable | 1.08M | 1.52M | 1.92M | 3.42M | 2.13M |
| Accrued Expenses | 2.73M | 4.18M | 6.88M | 3.50M | 2.21M |
| Total Current Liabilities | 3.81M | 5.71M | 8.80M | 6.92M | 4.34M |
| Other Long-Term Liabilities | 404.99K | 404.99K | 411.76K | 535.03K | 491.39K |
| Total Liabilities | 4.21M | 6.11M | 9.21M | 7.46M | 4.84M |
| Common Stock | 24.00 | 23.00 | 20.00 | 2.00 | 3.00 |
| Additional Paid-In Capital | 166.09M | 162.53M | 132.48M | 5.47M | 5.04M |
| Retained Earnings | -165.10M | -154.61M | -132.38M | -105.09M | -80.35M |
| Total Common Equity | 989.15K | 7.92M | 104.19K | -99.63M | -75.31M |
| Shareholders' Equity | 989.15K | 7.92M | 104.19K | -4.46M | 15.65M |
| Total Liabilities & Equity | 5.20M | 14.04M | 9.32M | 3.00M | 20.48M |
| Net Cash (Debt) | 4.43M | 13.16M | 8.64M | 2.96M | 20.45M |
| Net Cash Per Share | 0.19 | 0.63 | 1.03 | 2.06 | 16.89 |
| Filing Date Shares Outstanding | 24.01M | 23.71M | 19.53M | 1.69M | 1.21M |
| Total Common Shares Outstanding | 24.01M | 23.25M | 19.53M | 1.69M | 1.21M |
| Working Capital | 942.75K | 7.94M | 405.40K | -3.93M | 16.14M |
| Book Value Per Share | 0.04 | 0.34 | 0.01 | -58.93 | -62.21 |
| Tangible Book Value | 989.15K | 7.92M | 104.19K | -99.63M | -75.31M |
| Tangible Book Value Per Share | 0.04 | 0.34 | 0.01 | -58.93 | -62.21 |
Cash flow statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Net Income | -20.45M | -22.23M | -27.29M | -24.74M | -20.16M |
| Stock-Based Compensation | 6.04M | 6.05M | 2.00M | 423.54K | 654.07K |
| Other Operating Activities | 158.75K | 20.25K | 2.35M | 123.46K | -20.38K |
| Change in Accounts Payable | -2.12M | -512.54K | -1.50M | 1.29M | 586.26K |
| Change in Other Net Operating Assets | -3.46M | -2.53M | 2.60M | 1.28M | 1.15M |
| Operating Cash Flow | -19.84M | -19.21M | -21.84M | -21.63M | -17.79M |
| Short-Term Debt Issued | 5.70M | ||||
| Total Debt Issued | 5.70M | ||||
| Short-Term Debt Repaid | -200.00K | ||||
| Total Debt Repaid | -200.00K | ||||
| Net Debt Issued (Repaid) | 5.50M | ||||
| Issuance of Common Stock | 18.07M | 24.03M | 23.96M | ||
| Other Financing Activities | 225.55K | -302.82K | -1.93M | ||
| Financing Cash Flow | 17.77M | 23.72M | 27.53M | 4.13M | 19.26M |
| Net Cash Flow | -2.07M | 4.52M | 5.68M | -17.49M | 1.46M |
| Levered Free Cash Flow | -12.48M | -11.04M | -12.39M | -12.64M | |
| Unlevered Free Cash Flow | -12.47M | -11.03M | -12.38M | -12.61M | |
| Cash Interest Paid | 70.96K | 70.96K | 71.03K | ||
| Cash Income Tax Paid | 800.00 | 800.00 | 800.00 | ||
| Change in Working Capital | -5.58M | -3.05M | 1.10M | 2.57M | 1.73M |
Ratios
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Market Capitalization | 18.43M | 142.25M | 155.47M | ||
| Enterprise Value | 14.00M | 125.32M | 141.95M | ||
| Last Close Price | 0.34 | 6.12 | 7.96 | ||
| PB Ratio | 8.14 | 17.95 | 1,492.25 | ||
| P/TBV Ratio | 18.63 | 17.95 | 1,492.25 | ||
| Net Debt / Equity Ratio | -4.47 | -1.66 | -82.94 | 0.66 | -1.31 |
| Quick Ratio | 1.16 | 2.31 | 0.98 | 0.43 | 4.71 |
| Current Ratio | 1.25 | 2.39 | 1.05 | 0.43 | 4.71 |
| Return on Equity (ROE) | -553.75% | -442.40% | |||
| Return on Assets (ROA) | -213.40% | -120.40% | -255.41% | -132.96% | |
| Return on Capital Employed (ROCE) | -1,490.00% | -270.10% | -4,876.60% | 636.30% | -125.20% |
| Earnings Yield | -264.37% | -15.63% | -17.55% | ||
| Buyback Yield / Dilution | -32.81% | -151.07% | -483.48% | -18.54% |